Vytrus Biotech, member of CataloniaBio & HealthTech, has closed a 2.3 million euros capital round, through a capital increase and the sale of shares, in which it has increased and renewed part of its shareholder base.
A portion of the funds, 1.2 million euros, was raised through a capital increase led by Boyser, a family office linked to one of the founding families of Fluidra, in which minority shareholders also participated. The price of the capital increase was set at 2.37 € per share.
The funds raised in the capital increase will be used to finance the company's expansion, focusing on inorganic operations and the introduction of new technologies.
Vytrus has also brought in several institutional investors to its shareholder base, who will collectively hold around 5% of the capital. The transactions were executed through block trades for an amount close to 1.1 million euros at the same price as the capital increase.
The company is thus strengthening its shareholder pool, with the aim of accompanying the expansion planned in the Strategic Plan until 2027. After the financing round, the founders of the biotech company, Albert Jané and Òscar Expósito, jointly maintain 34% of the capital.
Albert Jané, co-founder of Vytrus, stated that "with this capital round, we are consolidating a first-class shareholder pool, who will be key to the company's expansion strategy in the coming years".
Comments